Skip to main content
Clinical Trials/NCT01673269
NCT01673269
Completed
Not Applicable

Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD

Texas Tech University Health Sciences Center, El Paso1 site in 1 country60 target enrollmentJuly 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Choledocholithiasis
Sponsor
Texas Tech University Health Sciences Center, El Paso
Enrollment
60
Locations
1
Primary Endpoint
the frequency of bacteremia after ERCP with direct cholangioscopic examination of the CBD
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

When a doctor performs Endoscopic retrograde cholangiopancreatography "ERCP" (Endoscopy to examine the bile duct) a flexible tube is inserted into the mouth and into the stomach. The tube passes beyond the stomach and into an opening in the liver called the bile duct. Another small flexible endoscope is inserted inside the ERCP scope to directly visualize the bile duct to ensure that there are no cancers or stones in the bile duct and occasionally to take a sample from the bile duct. The purpose of our study is to examine wither performing this procedure can transmit bacteria from the bile duct to the main blood stream.

Detailed Description

This is a prospective study to measure the frequency of bacteremia in patients undergoing ERCP with direct cholangioscopic examination of the Common Bile Duct "CBD". A blood culture will be drawn from patients prior to the procedure, 5 minutes after the procedure and 30 minutes after the procedure. The patient will be followed up for 7 days after procedure for fever and sepsis. The estimated sample size is 60 patients.

Registry
clinicaltrials.gov
Start Date
July 2012
End Date
October 2013
Last Updated
8 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Texas Tech University Health Sciences Center, El Paso
Responsible Party
Principal Investigator
Principal Investigator

Mohamed O Othman

Assistant Professor

Texas Tech University Health Sciences Center, El Paso

Eligibility Criteria

Inclusion Criteria

  • 1- Adult patients (18-80) who are undergoing ERCP with direct cholangioscopic examination of the common bile duct to ensure the clearance of the common bile duct from stones.
  • 2- Adult patients (18-80) who are undergoing ERCP with direct cholangioscopic examination of the common bile duct for stone removal.
  • 3- Adult patients (18-80) who are undergoing ERCP with direct cholangioscopic examination of the common bile duct for tissue acquisition from the common bile duct mass.
  • 4- Adult patients (18-80) who are undergoing ERCP with direct cholangioscopic examination of the common bile duct for tissue acquisition from common bile duct strictures.

Exclusion Criteria

  • 1- Patients younger than 18 yrs old or older than 80 yrs. 2- Pregnant patients. 3- Patient with ascending cholangitis, pneumonia or urinary tract infection 4- Patients who received antibiotics in the last 2 weeks prior to the procedure.

Outcomes

Primary Outcomes

the frequency of bacteremia after ERCP with direct cholangioscopic examination of the CBD

Time Frame: 5 minutes and 30 minutes

To measure the frequency of bacteremia after ERCP with direct cholangioscopic examination of the CBD by obtaining blood culture 5 minutes and 30 minutes after the procedure

Secondary Outcomes

  • To measure the frequency of fever or sepsis after ERCP with direct cholangioscopic examination of the CBD(within 24 hours and one week of the procedures.)

Study Sites (1)

Loading locations...

Similar Trials